Benchmark dose modeling of in vitro genotoxicity data: A reanalysis

被引：11

作者：

Guo X. ^{[1
]}

Mei N. ^{[1
]}

机构：

[1] Division of Genetic and Molecular Toxicology, National Center for Toxicological Research, Jefferson, AR

来源：

Toxicological Research | 2018年 / 34卷 / 4期

关键词：

Benchmark dose; In vitro genotoxicity; Mouse lymphoma assay; Quantitative analysis;

D O I：

10.5487/TR.2018.34.4.303

中图分类号：

学科分类号：

摘要：

The methods of applied genetic toxicology are changing from qualitative hazard identification to quantitative risk assessment. Recently, quantitative analysis with point of departure (PoD) metrics and benchmark dose (BMD) modeling have been applied to in vitro genotoxicity data. Two software packages are commonly used for BMD analysis. In previous studies, we performed quantitative dose-response analysis by using the PROAST software to quantitatively evaluate the mutagenicity of four piperidine nitroxides with various substituent groups on the 4- position of the piperidine ring and six cigarette whole smoke solutions (WSSs) prepared by bubbling machinegenerated whole smoke. In the present study, we reanalyzed the obtained genotoxicity data by using the EPA's BMD software (BMDS) to evaluate the inter-platform quantitative agreement of the estimates of genotoxic potency. We calculated the BMDs for 10%, 50%, and 100% (i.e., a two-fold increase), and 200% increases over the concurrent vehicle controls to achieve better discrimination of the dose-responses, along with their BMDLs (the lower 95% confidence interval of the BMD) and BMDUs (the upper 95% confidence interval of the BMD). The BMD values and rankings estimated in this study by using the EPA's BMDS were reasonably similar to those calculated in our previous studies by using PROAST. These results indicated that both software packages were suitable for dose-response analysis using the mouse lymphoma assay and that the BMD modeling results from these software packages produced comparable rank orders of the mutagenic potency. © 2018 Korean Society of Toxicology.

引用

页码：303 / 310

页数：7

共 33 条

[1]

Crump K.S., A new method for determining allow able daily intakes, Fundam. Appl. Toxicol, 4, pp. 854-871, (1984)

[2]

Cronin M.T.D., Enoch S.J., Mellor C.L., Przybylak K.R., Richarz A.N., Madden J.C., In silico prediction of organ level toxicity: Linking chemistry to adverse effects, Toxicol. Res, 33, pp. 173-182, (2017)

[3]

Brandon E.F., Bulder A.S., van Engelen J.G., Mahieu C.M., Mennes W.C., Pronk M.E., Rietveld A.G., van de Ven B.M., Ten Voorde S.E., Wolterink G., Slob W., Zeilmaker M.J., Bessems J.G., Does EU legislation allow the use of the Benchmark Dose (BMD) approach for risk assessment?, Regul. Toxicol. Pharmacol, 67, pp. 182-188, (2013)

[4]

Methods for derivation of inhalation reference concentrations and application of inhalation dosimetry, (1994)

[5]

What is benchmark dose software (BMDS), (1999)

[6]

Barnes D.G., Daston G.P., Evans J.S., Jarabek A.M., Kavlock R.J., Kimmel C.A., Park C., Spitzer H.L., Benchmark Dose Workshop: criteria for use of a benchmark dose to estimate a reference dose, Regul. Toxicol. Pharmacol, 21, pp. 296-306, (1995)

[7]

Mattison D.R., Sandler J.D., Summary of the workshop on issues in risk assessment: quantitative methods for developmental toxicology, Risk Anal, 14, pp. 595-604, (1994)

[8]

Slikker W., Crump K.S., Andersen M.E., Bellinger D., Biologically based, quantitative risk assessment of neurotoxicants, Fundam. Appl. Toxicol, 29, pp. 18-30, (1996)

[9]

Van Landingham C.B., Allen B.C., Shipp A.M., Crump K.S., Comparison of the EU T25 single point estimate method with benchmark dose response modeling for estimating potency of carcinogens, Risk Anal, 21, pp. 641-656, (2001)

[10]

Burgoon L.D., Zacharewski T.R., Automated quantitative dose-response modeling and point of departure determination for large toxicogenomic and high-throughput screening data sets, Toxicol. Sci, 104, pp. 412-418, (2008)

← 1 2 3 4 →